AIs vs. Tamoxifen for Pre-Menopausal Women W/ Early-Stage, HR+
Study Compares Aromatase Inhibitors vs. Tamoxifen for Pre-Menopausal Women With Early-Stage, Hormone Receptor-Positive Breast Cancer
December 15, 2021
Pre-menopausal women diagnosed with early-stage, hormone receptor-positive breast cancer who took an aromatase inhibitor along with ovarian suppression after surgery had a 3.2% lower risk of recurrence than women who took tamoxifen after surgery. Still, there was no difference in overall survival. Read more...